In this presentation from Lymphoma & Myeloma 2016, Dr. Jeremy S. Abramson argues for the use of novel agents for a 60 year patient with follicular lymphoma who has relapsed less than two years after receiving upfront R-CHOP therapy.
Click to Earn CME Credit: http://bit.ly/2mFKBrY
© 2016 Imedex, LLC.
Advertisement